Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

BUY
$18.66 - $38.58 $329,908 - $682,094
17,680 Added 51.62%
51,931 $2 Million
Q1 2023

May 10, 2023

BUY
$21.53 - $26.8 $44,653 - $55,583
2,074 Added 6.45%
34,251 $792,000
Q4 2022

Feb 13, 2023

BUY
$18.63 - $27.35 $48,885 - $71,766
2,624 Added 8.88%
32,177 $843,000
Q3 2022

Nov 10, 2022

BUY
$17.51 - $23.37 $49,395 - $65,926
2,821 Added 10.55%
29,553 $581,000
Q2 2022

Aug 12, 2022

BUY
$12.59 - $18.8 $336,555 - $502,561
26,732 New
26,732 $467,000

Others Institutions Holding KDNY

About CHINOOK THERAPEUTICS, INC.


  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.